IDSA Guidance on the Treatment of AmpC β-Lactamase–Producing Enterobacterales, Carbapenem-Resistant Acinetobacter baumannii, and Stenotrophomonas maltophilia Infections - infectology.by

infectologyby@gmail.com

previous post: SHEA statement on antibiotic stewardship in hospitals during public health emergencies (2022, ENG)
next post: IDSA 2022 Guidance on the Treatment of Extended-Spectrum β-lactamase Producing Enterobacterales (ESBL-E), Carbapenem-Resistant Enterobacterales (CRE)